Trial Profile
Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination with Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin; Gemcitabine
- Indications Urogenital cancer
- Focus Adverse reactions
- 26 Sep 2023 Planned End Date changed from 30 Sep 2022 to 30 Sep 2024.
- 26 Sep 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Sep 2024.
- 21 Feb 2022 Planned End Date changed from 30 Sep 2021 to 30 Sep 2022.